Manufacture

A breakthrough in transgenic mice opens the door to “Humabodies.”

How can we achieve gender parity in drug dosing?

We speak with Laertis Ikonomou and Dan Weiss about the ISCT's work to combat unproven cell therapies.

What challenges and opportunities do immunotherapy developers face?

Cell and gene therapies are now considered mainstream therapeutic modalities – with revolutionary potential. But that hasn’t always been the case…

Queenie Jang reveals how the ISCT created an interactive virtual conference in under two months.

Joslin Diabetes Center researchers take the first steps towards an autologous cell therapy for obesity.

The industry must overcome enormous challenges in order to take the next steps in induced pluripotent stem cell technology.

How can we reduce animal testing in quality control procedures?

How to drive antibody drug development and manufacture forward safely and quickly.